For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

The decision comes as the company is discontinuing clinical testing of a CLDN6-targeted CAR T-cell therapy in testicular cancer.

The US subsidiary will focus on advancing PolTreg's pipeline in these new territories, including its lead candidate PTG-007 in type 1 diabetes.

The biotech plans to use one-year follow-up data from the Phase II/III trial to support a biologics license application for OCU410ST in 2027.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

NEW YORK – SunRock Biopharma and Escugen on Tuesday said they've partnered to co-develop the antibody-drug conjugate (ADC) SRB123 as a treatment for solid tumors that overexpress CCR9. Escugen, ...

NEW YORK – OCCAM Immune, a research organization within Mount Sinai, announced a long-term partnership this week with the Cancer Research Institute to identify which cancer patients respond best to ...

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.